<div id="readability-page-1"><p>Elo Mutual Pension Insurance Co cut its stake in shares of  Zoetis Inc. (NYSE:ZTS - Free Report) by 4.7% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 41,344 shares of the company's stock after selling 2,022 shares during the period. Elo Mutual Pension Insurance Co's holdings in Zoetis were worth $6,736,000 at the end of the most recent quarter.</p><ul><li>Which Pet Stock Should Get Your Tail Wagging in 2024?</li></ul><p>Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of  Zoetis by 4.3% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,664,867 shares of the company's stock valued at $271,889,000 after acquiring an additional 68,249 shares in the last quarter.  Korea Investment CORP raised its stake in  Zoetis by 11.6% in the 4th quarter. Korea Investment CORP now owns 328,156 shares of the company's stock valued at $53,466,000 after purchasing an additional 34,174 shares during the last quarter.  Tyler Stone Wealth Management lifted its holdings in  Zoetis by 13.2% in the 4th quarter. Tyler Stone Wealth Management now owns 2,405 shares of the company's stock valued at $392,000 after purchasing an additional 281 shares in the last quarter.  United Super Pty Ltd in its capacity as Trustee for the Construction &amp; Building Unions Superannuation Fund boosted its stake in  Zoetis by 2.4% during the 4th quarter. United Super Pty Ltd in its capacity as Trustee for the Construction &amp; Building Unions Superannuation Fund now owns 234,860 shares of the company's stock worth $38,266,000 after purchasing an additional 5,400 shares during the last quarter.  Finally, Murphy &amp; Mullick Capital Management Corp purchased a new stake in shares of  Zoetis during the fourth quarter worth $44,000. 92.80% of the stock is owned by hedge funds and other institutional investors. </p><h2>Zoetis Stock Up 1.4 %</h2><p>Shares of NYSE:ZTS opened at $165.12 on Friday. The company has a market capitalization of $73.94 billion, a price-to-earnings ratio of 30.19, a PEG ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.33. The business has a 50-day moving average price of $166.46 and a 200 day moving average price of $174.87. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. </p><ul><li>MarketBeat Week in Review – 07/31 - 08/04</li></ul><p>Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion.  Sell-side analysts expect that  Zoetis Inc. will post 6.07 EPS for the current year. </p><h2>Zoetis Dividend Announcement</h2><p>The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.21%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's payout ratio is 36.56%. </p><h2>Wall Street Analysts Forecast Growth</h2><ul><li>Rising Dividend Make Zoetis a Doggone Winner</li></ul><p>A number of research firms recently weighed in on ZTS. Leerink Partnrs upgraded shares of Zoetis to a &#34;strong-buy&#34; rating in a research report on Monday, December 2nd. Piper Sandler boosted their target price on Zoetis from $200.00 to $205.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday, February 27th. Stifel Nicolaus cut their price target on Zoetis from $210.00 to $180.00 and set a &#34;buy&#34; rating for the company in a report on Tuesday, January 7th. Morgan Stanley lowered their price objective on Zoetis from $243.00 to $238.00 and set an &#34;overweight&#34; rating on the stock in a research note on Friday, February 14th. Finally, UBS Group initiated coverage on Zoetis in a research note on Monday, December 9th. They issued a &#34;neutral&#34; rating and a $196.00 target price for the company. One investment analyst  has rated the stock with a hold rating, ten have issued  a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Buy&#34; and a consensus price target of $215.90.</p><p><b>Read Our Latest Research Report on ZTS</b></p><h2>Insider Activity at Zoetis</h2><p>In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,862 shares of company stock worth $312,254 in the last three months. 0.16% of the stock is owned by company insiders. </p><h2>About Zoetis</h2> (Free Report)<p>Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Zoetis</li><li>What Are the U.K. Market Holidays? How to Invest and Trade</li><li>Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell </li><li>What Are Dividend Achievers? An Introduction</li><li>Top 3 Beverage Stocks Pouring Out Profits</li><li>Canada Bond Market Holiday: How to Invest and Trade </li><li>CarMax and Carvana: Steering the Used Car Market</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpUUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpUUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Zoetis Right Now?</h2><p>Before you consider Zoetis, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.</p><p>While Zoetis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Elo Mutual Pension Insurance Co reduced its stake in Zoetis Inc. (NYSE:ZTS) by 4.7% in Q4, now holding 41,344 shares valued at $6.74 million. Other institutional investors also adjusted their stakes, with Mitsubishi UFJ Asset Management increasing its position by 4.3%. Zoetis shares opened at $165.12, with a market cap of $73.94 billion. The company reported Q4 earnings of $1.40 per share, exceeding estimates. A quarterly dividend of $0.50 per share will be paid on June 3rd. Analysts have mixed ratings, with a range of price targets from $180 to $205.</p>

Zoetis Inc. (NYSE:ZTS) Shares Sold by Elo Mutual Pension Insurance Co